Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00049582
Status:
TERMINATED
Last Update Posted:
2013-09-30
First Post:
2002-11-12
Brief Title:
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Adult Acute Myeloid Leukemia With 11q23 MLL Abnormalities |
| Adult Acute Myeloid Leukemia With Inv16p13q22 |
| Adult Acute Myeloid Leukemia With t1517q22q12 |
| Adult Acute Myeloid Leukemia With t1616p13q22 |
| Adult Acute Myeloid Leukemia With t821q22q22 |
| Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative |
| de Novo Myelodysplastic Syndromes |
| MyelodysplasticMyeloproliferative Neoplasm Unclassifiable |
| Previously Treated Myelodysplastic Syndromes |
| Untreated Adult Acute Myeloid Leukemia |
| Recurrent Adult Acute Myeloid Leukemia |
| Secondary Acute Myeloid Leukemia |
| Secondary Myelodysplastic Syndromes |
Keywords: